| Title |
Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma
|
|---|---|
| Published in |
Archivum Immunologiae et Therapiae Experimentalis, January 2017
|
| DOI | 10.1007/s00005-016-0442-6 |
| Pubmed ID | |
| Authors |
Aleksandra Butrym, Piotr Łacina, Justyna Rybka, Monika Chaszczewska-Markowska, Grzegorz Mazur, Katarzyna Bogunia-Kubik |
| Abstract |
Multiple myeloma (MM) is a plasma-cell malignancy derived from an early precursor of the B-cell lineage characterised by bone-marrow infiltration, lytic bone lesions, and the presence of a monoclonal protein in serum and/or urine. Interferon regulatory factor 4 (IRF4) is a critical transcriptional regulator in B-cell development and function that is required during immune response for lymphocyte activation and the generation of immunoglobulin-secreting plasma cells. Immunomodulatory drugs, derivatives of thalidomide, are commonly used in therapy against MM. They are known to target a protein called cereblon (CRBN); however, the exact mechanism remains unknown. The present study aimed to assess the association of two (rs12203592 and rs872071) polymorphisms within the IRF4 gene and two (rs711613 and rs1045433) in the CRBN gene with MM susceptibility, progression, and response to treatment. For this purpose, 144 MM patients and 126 healthy individuals were genotyped for the IRF4 and CRBN alleles. The presence of the IRF4 (rs872071) G allele was more frequently detected in patients than healthy individuals (OR 1.78; P = 0.034), and this relationship was especially pronounced in women (OR 2.83; P = 0.012). The CRBN (rs711613) A allele-carriers were better responders to the treatment (P = 0.012), in particular to thalidomide including therapy (P = 0.023). These results underline the prognostic significance of the IRF4 and CRBN polymorphisms in patients with MM. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 75% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 40 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 8 | 20% |
| Researcher | 7 | 18% |
| Student > Bachelor | 5 | 13% |
| Other | 3 | 8% |
| Professor | 2 | 5% |
| Other | 6 | 15% |
| Unknown | 9 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 9 | 23% |
| Medicine and Dentistry | 8 | 20% |
| Agricultural and Biological Sciences | 3 | 8% |
| Business, Management and Accounting | 2 | 5% |
| Engineering | 2 | 5% |
| Other | 5 | 13% |
| Unknown | 11 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 April 2017.
All research outputs
#14,324,882
of 22,947,506 outputs
Outputs from Archivum Immunologiae et Therapiae Experimentalis
#219
of 385 outputs
Outputs of similar age
#230,643
of 422,244 outputs
Outputs of similar age from Archivum Immunologiae et Therapiae Experimentalis
#4
of 9 outputs
Altmetric has tracked 22,947,506 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 385 research outputs from this source. They receive a mean Attention Score of 4.0. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 422,244 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.